Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000597644 | SCV000709234 | uncertain significance | not provided | 2017-06-15 | criteria provided, single submitter | clinical testing | |
Center for Human Genetics, |
RCV000659310 | SCV000781121 | likely benign | Connective tissue disorder | 2016-11-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000597644 | SCV001778962 | uncertain significance | not provided | 2023-07-04 | criteria provided, single submitter | clinical testing | Identified in a patient with a clinical diagnosis of blindness in published literature (Dineiro et al., 2020); Not located in the triple helical region, where the majority of pathogenic missense variants occur (HGMD; Acke et al., 2014); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 32483926) |
Invitae | RCV000597644 | SCV002109240 | benign | not provided | 2024-01-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002532666 | SCV003695159 | uncertain significance | Inborn genetic diseases | 2021-10-26 | criteria provided, single submitter | clinical testing | The c.1522A>G (p.T508A) alteration is located in exon 13 (coding exon 13) of the COL11A1 gene. This alteration results from a A to G substitution at nucleotide position 1522, causing the threonine (T) at amino acid position 508 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |